China Revolutionizes the Global Pharmaceutical Market: Billions at Stake in Biotech and the Race for Innovation - Analysis

• China is revolutionizing the global pharmaceutical industry, emerging as a biotechnology innovation hub and attracting billion-dollar deals. The most sensational cases in May and June are evidence of this.

• In May, Pfizer signed a record deal with China's 3SBio, paying a $1.25 billion upfront (with potential up to $6 billion total) for a bispecific cancer drug. Soon after, in June, Bristol-Myers Squibb paid $1.5 billion upfront to BioNTech for a similar drug originally developed by China's Biotheus. These deals underscore the growing confidence in Chinese biotechs, now seen as primary sources of cutting-edge innovation.

• This success is fueled by substantial government investment, a large talent pool, and a more flexible regulatory regime. However, China's rise generates grave concerns in Washington, which fears technological dominance and reports allegations of intellectual property theft, prompting the United States to invest heavily in its biotech sector to keep pace.

GettyImages

The global pharmaceutical industry is undergoing a profound transformation. China, traditionally viewed as an emerging market or a manufacturing base, is rapidly establishing itself as a global biotech innovation hub, attracting billion-dollar deals from the world's largest pharmaceutical companies. This rapid ascent isn't just reshaping R&D strategies; it's positioning China as a crucial source of cutting-edge drugs, particularly in oncology.

While much attention focuses on the US-China competition in artificial intelligence, new studies highlight Beijing's swift rise in biotechnology, especially in pharmaceutical and agricultural development.

According to the Harvard Belfer Center for Science and International Affairs, in its recent "Critical and Emerging Technologies Index" (covering AI, biotech, semiconductors, space, and quantum computing), among the five critical tech sectors, "China has the most immediate opportunity to overtake the United States in biotechnology." While the US still leads in all five areas, "the narrowing gap between the U.S. and China [in the biotechnology sector] suggests that future developments could rapidly alter the global balance of power," the report states.

This assessment reflects Washington's growing concerns. The U.S. National Security Commission on Emerging Biotechnology adopted a more urgent tone in an April report, citing two years of research: "There will be a ChatGPT moment for biotechnology, and if China gets there first, no matter how fast we run, we will never catch up," the bipartisan congressional commission stated. "Our window to act is closing. We need a two-track strategy: accelerate American innovation and slow down Chinese innovation." The commission recommends the U.S. government invest at least $15 billion over the next five years to support the domestic biotechnology sector.

Sensational Deals Reshaping the Rules

Recent years have seen financially imposing deals that highlight Western Big Pharma's confidence and investment appetite in Chinese innovation:

• Pfizer and 3SBio: A Record Deal Worth Over $6 Billion (May 2025) In late May, American pharmaceutical giant Pfizer inked a groundbreaking agreement with China's 3SBio of Shenyang. Pfizer secured global licensing rights (excluding China, where 3SBio retains its rights) for SSGJ-707, a promising experimental anti-cancer drug—a bispecific antibody targeting two important cellular pathways (PD-1 and VEGF). The most striking aspect was the record upfront payment of $1.25 billion from Pfizer. Additionally, there's a $100 million equity investment in 3SBio, and 3SBio could receive up to $4.8 billion in milestone payments tied to development, regulatory, and commercial achievements, plus sales royalties. This marks the highest upfront payment ever made by an international pharmaceutical company for a molecule developed by a Chinese biotech, underscoring the significant potential recognized in SSGJ-707.

• Bristol-Myers Squibb (BMS) and BioNTech: Chinese Innovation via Acquisition (June 2025) Just two weeks after Pfizer's announcement, Bristol-Myers Squibb followed suit, announcing a global partnership with Germany's BioNTech (globally known for its COVID-19 vaccine developed with Pfizer). The agreement involves the co-development and co-commercialization of BNT327 (or PM8002), another bispecific oncology antibody. BMS's upfront payment to BioNTech totals $1.5 billion, with an additional $2 billion guaranteed by 2028, and potential milestones reaching $7.6 billion. What makes this deal noteworthy is BNT327's origin: the drug was originally developed by China's Biotheus, which BioNTech acquired for $800 million in late 2024. This case demonstrates that Chinese innovation is not only a direct source of licenses but also a driver of strategic acquisitions by Western companies looking to integrate Chinese pipelines into their strategies.

• Akeso and Ivonescimab: Challenging Keytruda (September 2024) In September 2024, an event initially went largely unnoticed outside industry circles but ultimately shook the biotech sector: Akeso, a lesser-known Chinese biotech founded almost a decade ago, presented groundbreaking clinical results for its new lung cancer drug, Ivonescimab. In a clinical study conducted in China, Ivonescimab demonstrated superiority over Keytruda, Merck's blockbuster drug that has generated over $130 billion in sales. Clinical data revealed that patients treated with Ivonescimab waited 11.1 months before their tumors began to grow again, significantly better than the 5.8 months achieved with Keytruda. Within days, shares of Summit Therapeutics, Akeso's U.S. partner for commercialization in North America and Europe, more than doubled to a record high. This episode, termed a "watershed moment" by experts, helped spotlight China's innovative capabilities on an international scale.

These agreements aren't isolated incidents; they represent the tip of an accelerating trend. In 2024, British pharmaceutical giant AstraZeneca announced a $2.5 billion investment in an R&D center in Beijing and inked a $1.92 billion deal with China's CSPC Pharmaceutical Group to develop cardiovascular drugs. During the same period, Merck entered a $2 billion agreement with China's Hansoh Pharmaceutical for an experimental weight-loss pill. These deals underscore that Chinese companies are no longer just R&D or manufacturing service providers; they are becoming primary sources of innovation in biotechnology.

The Rise of Chinese Biotechnology: From "Me-Too" to Global Innovation

Until the 1980s, when China opened its economy, most of its pharmaceutical companies were state-owned. For much of the past 40 years, Chinese biotech companies primarily focused on replicating existing drugs, known as "me-too" drugs. This approach allowed them to build manufacturing and basic research capabilities.

However, over the last decade, there's been a decisive shift. Chinese companies have invested heavily in innovation, developing advanced, original drugs that directly compete with Western products. It's no longer just about imitation; it's about innovating with new molecules and next-generation therapies. This evolution has led to the signing of multi-billion dollar licensing deals with Western partners for global distribution of their products.

Rebecca Liang, a pharmaceutical analyst at AB Bernstein, commented, "The biotech industry was known to be growing very quickly in China, but very few thought of it as a real threat to major U.S. innovators. Now the threat is becoming concrete, because you're starting to see these next-generation drugs that are a kind of leap forward."

According to a research note from HSBC Qianhai Securities, China is becoming an innovation hub for the entire sector: the number of licensing deals surged from just 46 in 2017 to over 200 last year, with the total deal value skyrocketing from $4 billion in 2017 to a remarkable $57 billion last year. Data from market intelligence firm Mergermarket further indicates that large pharmaceutical transactions valued at $50 million or more involving Chinese companies increased by nearly 30% in 2024 compared to the previous year.

Cui Cui, managing director of healthcare research at Jefferies, emphasized that Chinese biotech companies' research capabilities and development efficiency are catching up due to factors such as strong government support, foreign investment, and an abundance of domestic talent.

Reasons Behind China's Biotech Success

China's transformation into a global hub for billion-dollar biotech deals stems from a combination of strategic and structural factors:

1. Massive Investment and Government Support: The Chinese government has prioritized the biotech sector as a pillar for future development. Through its five-year bioeconomy plan (first launched in 2022), it has set ambitious goals in biopharmaceuticals, bio-agriculture, bio-manufacturing, and bio-security. This translates into enormous investments in R&D, the creation of state-guided funds, innovation centers, and the provision of subsidies and tax incentives for companies in the sector. Cities like Shanghai are investing to become innovation epicenters, including in medical AI. This support, as stated by Cynthia Y. Tong, a co-author of the Harvard report, extends to a more flexible regulatory regime and the ability to accelerate approval times, unlike the U.S., which tends to have longer approval processes and R&D periods.

2. A Vast Talent Pool: The sector's expansion has been fueled by the return of numerous Chinese scientists, researchers, and executives who trained and worked for years at leading Western institutions and pharmaceutical companies. These "returning brains" bring not only advanced skills but also an innovation- and internationalization-oriented mindset. This is bolstered by a large and growing pool of science and technology graduates, with China boasting more human talent than the United States.

3. Innovation and Specialization in Advanced Therapies: Chinese companies aren't just replicating existing drugs. They are investing heavily in developing original molecules (novel drugs) and have become leaders in innovative drug classes like antibody-drug conjugates (ADCs), cell therapies (CAR-T), and, as the aforementioned deals demonstrate, bispecific antibodies. These therapies represent the new frontier in the fight against cancer and other complex diseases.

4. A Colossal and Growing Domestic Market: China is the world's second-largest pharmaceutical market. Access to such a vast population, with a growing middle class and increasing per capita healthcare spending, offers a unique opportunity for Chinese companies to rapidly test and validate their drugs and generate significant sales volumes before even looking to foreign markets.

5. Competitive Costs, Efficiency, and Manufacturing Dominance: While R&D costs are rising in China, they often remain more competitive than in Western countries. Furthermore, the country has developed a robust ecosystem of contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs), offering efficient, high-quality services that support the entire drug lifecycle. The Harvard Belfer Center highlighted that China's strengths in the biotech sector partly stem from its "dominance in pharmaceutical production and manufacturing."

Washington's Concerns and Allegations of Technology Theft

China's rapid ascent in biotech has sparked increasing concerns in Washington, further fueled by numerous allegations of intellectual property theft. The U.S. National Security Commission on Emerging Biotechnology has expressed an urgent tone, fearing that Chinese dominance in the sector could translate into a critical form of influence, similar to Chinese rare earth restrictions already impacting Western manufacturers.

The Office of the Director of National Intelligence (ODNI) warned in its February 2024 annual threat assessment that Beijing is prioritizing biotechnology and accelerating its scientific and technological development through intellectual property theft and other methods to gain economic, political, and military advantages. The U.S. government has repeatedly accused the People's Republic of China of state-sponsored economic espionage and intellectual property infringement, in violation of international trade agreements. The U.S. Department of Justice has reported cases where individuals associated with China have been accused of stealing trade secrets, for example, in exosome research and exosome isolation from American research institutions to sell them in China.

The concern is that, just as Chinese restrictions on rare earths begin to hit automobile manufacturers, Chinese dominance in the biotechnology sector could evolve into another form of Beijing's leverage over the United States and other countries. China, through programs like the "Thousand Talents Plan," has leveraged the openness of U.S. institutions to acquire pre-competitive research and intellectual capital, severely impacting the U.S. economy and competitiveness. The FBI opened over 1,000 intellectual property violation cases involving individuals associated with the People's Republic of China in 2020, with Director Christopher Wray stating that the FBI opens a new Chinese counterintelligence investigation every 12 hours.

"Currently, the U.S. government lacks a cohesive, intentional biotechnology strategy, while China is gaining ground due to its aggressive, carefully coordinated state-led initiatives," the U.S. security commission stated.

Even as China rapidly develops its biotech sector, reports from U.S. biotech hubs in Cambridge and Boston reveal layoffs and empty labs. This contrasts with China's "grand strategy," which has long utilized multi-year plans and preferential state policies to encourage the development of key technologies, with high-level support for biotechnology dating back to 2007.

Eric Rosenbach, director of the Defense, Emerging Technologies, and Strategy program at Harvard's Belfer Center and former Chief of Staff for the U.S. Department of Defense, expects the U.S. to exert greater pressure on China. "The likelihood of U.S.-China cooperation on any topic is very low, and in some ways it's even less likely on biotechnology and AI," due to the congressional report.

In conclusion, China has transformed from a mere consumer market into a global engine of biotechnology innovation. Its ability to develop cutting-edge therapies, supported by massive investments and a rapidly evolving ecosystem of talent and infrastructure, makes it an indispensable partner and a crucial source of new molecules for the global pharmaceutical industry. This ascent, however, comes with increasing geopolitical tensions and concerns regarding intellectual property protection, posing new and complex strategic challenges for Western nations.